Amp Volatility Score
Catalyst Info & Data Links
TITLE: FIRDAPSE®(Amifampridine) for Myasthenia gravis (MG) - Phase 3
ClinicalTrial.gov (NCT03304054): Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Firdapse® (amifampridine) 10 mg tablets is an oral, nonspecific, voltage-dependent, potassium (K+) channel blocker that causes depolarization of the presynaptic membrane and slows or inhibits repolarization. This action results in the opening of slow voltage-dependent calcium (Ca2+) channels, allowing for a subsequent influx of Ca2+. In turn, it induces the exocytosis of synaptic vesicles containing Acetylcholine (ACh) to release more ACh into the synaptic cleft, enhancing neuromuscular transmission, and providing for improved muscle function.
Updated by JM
CPRX, Catalyst Pharma, Myasthenia gravis (MG), MUSK, Litigation, FIRDAPSE (Amifampridine)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post